Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects of decitabine when given together with or
without interferon alfa-2b, and the best dose of interferon alfa-2b, in treating patients
with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as decitabine,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Biological therapies, such as interferon alfa-2b, may stimulate
the immune system in different ways and stop tumor cells from growing. It is not yet known
whether decitabine is more effective when given with or without interferon alfa-2b in
treating solid tumors.